NCT05691660

A Study of TAS3731 in Healthy Adults

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and Multiple Dose Escalating Study of TAS3731 in Healthy Adults

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 238 (actual)
• Sponsor: Taiho Pharmaceutical Co., Ltd. · Industry
• Sex: Male
• Age: 18 Years – 39 Years
• Healthy volunteers: Accepted

Summary

To evaluate the safety of single and repeated administration of TAS3731.

Conditions

• Healthy Adult Males

Interventions

Type	Name	Description
DRUG	TAS3731 Dose1	Oral administration,1 day,QD
DRUG	TAS3731 Dose2	Oral administration,7 days,QD
DRUG	TAS3731 Dose3	Oral administration,7 days,BID
DRUG	Placebo	Oral administration, 1 day,QD
DRUG	Placebo	Oral administration, 7 days,QD
DRUG	Placebo	Oral administration, 7 days,BID

Timeline

• Start date: 2023-01-17
• Primary completion: 2024-05-21
• Completion: 2024-05-21
• First posted: 2023-01-20
• Last updated: 2024-08-14

Locations

1 site across 1 country: Japan